Safety Study of RPE65 Gene Therapy to Treat Leber Congenital Amaurosis
Clinical Trial of Gene Therapy for Leber Congenital Amaurosis Caused by RPE65 Mutations
|3||Active, not recruiting||
An Open Label Clinical Trial of Retinal Gene Therapy for Choroideremia
Long-Term Follow-Up Gene Therapy Study for Leber Congenital Amaurosis OPTIRPE65 (Retinal Dystrophy Associated With Defects in RPE65)
Safety and Efficacy Study of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy (LHON)
† Study has passed its completion date and status has not been verified in more than two years.